Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (94)
March 10, 2008
- Maurer's Healthcare Insight (93)
February 18, 2008
- Maurer's Healthcare Insight (92)
January 21, 2008
- Maurer's Healthcare Insight (91)
December 24, 2007
- Maurer's Healthcare Insight (90)
November 5, 2007
- Maurer's Healthcare Insight (89)
October 8, 2007
- Maurer's Healthcare Insight (88)
August 6, 2007
- Maurer's Healthcare Insight (87) Japan Is (Is Not) an Attractive Market Part 2 P. Reed Maurer
June 4, 2007
- Maurer's Healthcare Insight (86)
May 28, 2007
- Maurer's Healthcare Insight (85)
April 16, 2007
- Maurer's Healthcare Insight (84)
March 26, 2007
- Japan's Most Admired Pharma Companies in 2006 P. Reed Maurer
March 12, 2007
- Maurer's Healthcare Insight (83)
February 19, 2007
- 2006: When the Pendulum Swung P. Reed Maurer
January 8, 2007
- Maurer's Healthcare Insight (82)／Questions from the Floor P. Reed Maurer
December 18, 2006
- Maurer's Healthcare Insight (81)
November 20, 2006
- Maurer's Healthcare Insight (80)
October 23, 2006
- Maurer's Healthcare Insight (79) Back from the Saddle P. Reed Maurer
September 25, 2006
- Maurer's Healthcare Insight (78) Infinite Value of a Good Boss P. Reed Maurer
August 28, 2006
- Maurer's Healthcare Insight (77)
July 24, 2006
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…